Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Asbestosis
NCT05133453Not yet recruiting
- Sponsor
- Cairo University
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
01
Overview
Open-label trial of pirfenidone in asbestosis (2 arms), sponsored by Cairo University. Primary endpoints: Ventilatory function change at 12 months, Diffusion test at 12 months and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
asbestosis
Beyond the preview
Go deeper on NCT05133453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133453.